Medscape

AAN 2026: Anticipating Updates in Relapsing MS Diagnosis and Treatment

Dr Chu-Yueh Guo prepares to discover how the latest diagnostic criteria and breakthrough treatments are reshaping the ...
Medscape

Relapsing-Remitting Multiple Sclerosis

Insights from AAN 2026, including anticipated presentations, key takeaways, and how emerging research in RRMS may affect ...
Healio

Ublituximab demonstrates sustained benefit for relapsing MS in interim open-label analysis

Please provide your email address to receive an email when new articles are posted on . Adults either continued to receive ublituximab or switched from teriflunomide to ublituximab in this 3-year open ...
Healio

Comorbidities do not affect treatment for relapsing MS in Black, Hispanic patients

Please provide your email address to receive an email when new articles are posted on . The most common comorbidity for both subsets of the study population was obesity. Risk for infection-related ...
Seeking Alpha

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

--TG Therapeutics, Inc., today announced updated data presentations including new six-year data from the ULTIMATE I& II Phase 3 trials evaluating BRIUMVI ® in patients with relapsing forms of multiple ...
Seeking Alpha

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
Nasdaq

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in ...

– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in ...
Nasdaq

[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third ...

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...